GlassScriptPhysician profile
Harry Adhikari
NPI 1700582939
$7,495.51
in general payments reported to CMS, 2019-2025
35 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,957 · 2024: $3,074 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,495.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.14 | 2023-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $935.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $811.60 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.48 | 2023-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Lilly USA, LLC | $601.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $526.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $343.38 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.12 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $237.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $187.92 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.89 | 2024-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $133.83 | 2023-2024 | Xarelto |
| Dexcom, INC. | $129.13 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $126.73 | 2023-2025 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $123.31 | 2023-2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $111.44 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $86.96 | 2023-2024 | Belsomra, Dificid, Proquad |
| Cequr Corporation | $72.22 | 2024-2025 | Cequr Simplicity |
| Vanda Pharmaceuticals INC. | $68.52 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $62.11 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $51.36 | 2025 | Gemtesa |
| Corcept Therapeutics | $48.72 | 2024-2025 | Korlym |
| Ibsa Pharma INC. | $45.43 | 2024 | Tirosint, Licart |
| Actelion Pharmaceuticals US, INC. | $38.30 | 2025 | Opsynvi, Uptravi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.44 | 2024-2025 | Caplyta |
| Medtronic, INC. | $33.37 | 2024 | Interstim |
| Shield Therapeutics INC | $33.06 | 2023 | Accrufer |
| Astellas Pharma US INC | $30.14 | 2025 | Veozah |
| Radius Health, INC. | $27.21 | 2025 | |
| Verona Pharma, INC. | $24.17 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $23.91 | 2024 | Inspire |
| Phadia US INC. | $23.72 | 2025 | Immunocap |
| Novartis Pharmaceuticals Corporation | $22.10 | 2025 | |
| Viatris Specialty LLC | $19.34 | 2025 | Yupelri |
| Tactile Systems Technology INC | $15.02 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Adhikari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.